SNY - The Medicines Company Is Up 161% Year to Date but Here's a Better Way to Play the Drugmaker's Success
The Medicines Company (NASDAQ: MDCO) is up 161% this year, thanks in large part to the success of its cholesterol-lowering drug inclisiran.
In August, the company announced that one of its late-stage clinical trials, Orion-11, was positive, which was followed by a presentation a few days later at the European Society of Cardiology's ESC Congress 2019 that showed inclisiran produced placebo-adjusted cholesterol reductions of 54% over the 18-month study.
Last week, The Medicines Company said two more late-stage studies, Orion-9 and -10, met their endpoints. Again the company didn't initially release data from the studies -- it's saving them for the American Heart Association Scientific Sessions in November -- but the company noted that the efficacy and safety data "were at least as favorable as observed in ORION-11."